Day: June 1, 2022

Posted on

Ballet “One Thousand and One Nights” by great composer Fikrat Amirov staged in Bulgaria

On May 31, the Sofia Opera and Ballet Theater staged the ballet “One Thousand and One Nights” by great composer Fikrat Amirov on the occasion of the Independence Day of the Republic of Azerbaijan and the 30th anniversary of the establishment of diplomatic relations between Azerbaijan and Bulgaria.

The gala ballet, held with the support of the Embassy of the Republic of Azerbaijan in the Republic of Bulgaria and the International Turkic Culture and Heritage Foundation, was attended by Minister of Foreign Affairs of the Republic of Azerbaijan Jeyhun Bayramov and Minister of Foreign Affairs of the Republic of Bulgaria Teodora Genchovska, President of the International Turkic Culture and Heritage Foundation Gunay Afandiyeva, Bulgarian officials, representatives of the diplomatic corps in Bulgaria and numerous spectators.

Speaking at the opening of the evening, Minister Jeyhun Bayramov noted that the first democratic republic in the Muslim East was the Azerbaijan Democratic Republic, proclaimed in 1918, and that in 1991 the country restored its independence and underwent great development over three decades. He said that Azerbaijan has always been committed to the traditions of multiculturalism, and the ballet performed today is an example of multiculturalism as a joint project of Azerbaijani and Bulgarian artists. Minister Teodora Genchovska congratulated Azerbaijan on the occasion of the Independence Day and the 30th anniversary of the establishment of diplomatic relations, noting that the organization of the gala ballet also contributes to the development of bilateral relations in the field of culture. President of the International Turkic Culture and Heritage Foundation Gunay Afandiyeva stressed that Fikrat Amirov, whose 100th anniversary we are celebrating, is a genius composer not only of Azerbaijan but of the entire Turkic world, and emphasized the importance of the gala ballet in terms of promoting Turkic culture.

In a ballet staged under the direction of conductor Eyyub Guliyev and choreographed by Eldar Aliyev, Bulgarian ballet dancers gave the audience an unforgettable gala night. The ballet performance, which caused great interest and enthusiastic reception, attracted a full house.

Source: Azerbaijan State News Agency

Posted on

Azerbaijani FM meets with Bulgarian PM

As part of his official visit to the Republic of Bulgaria, Azerbaijan`s Foreign Minister Jeyhun Bayramov has met with Bulgarian Prime Minister Kiril Petkov.

Welcoming the Azerbaijani Foreign Minister, the Prime Minister stressed the importance of the current visit. Stating that Azerbaijan is assisting Bulgaria in the energy sector at a very important time for his country, Premier Kiril Petkov stressed the role of President of Azerbaijan Ilham Aliyev in this regard and noted that the Azerbaijani state is a reliable partner.

Minister Bayramov expressed gratitude for the warm welcome. It was noted that the high-level political relations between the two countries are accompanied by dynamic development in the economic sphere.

The sides exchanged views on the prospects for bilateral relations in a number of areas, including energy, economy, trade, information technology, transport, transit, education, culture, tourism and others. It was noted that the next meeting of the Joint Commission on Trade-Economic and Scientific-Technical Cooperation between the Republic of Azerbaijan and the Republic of Bulgaria will contribute to the further expansion of economic relations.

FM Jeyhun Bayramov informed the Prime Minister on the post-conflict situation in the region, restoration and reconstruction work carried out in the liberated areas, demining process, and steps taken by the Azerbaijani government towards peacebuilding.

The sides also discussed regional issues and other matters of mutual interest.

Source: Azerbaijan State News Agency

Posted on

Azerbaijan discusses development of energy cooperation with Italy and Kazakhstan

As part of the Baku Energy Week, Azerbaijan`s Energy Minister Parviz Shahbazov has met with Undersecretary of State at the Ministry of Ecological Transition of the Italian Republic Vannia Gava and Energy Minister of the Republic of Kazakhstan Bolat Akchulakov.

At the meeting with Undersecretary of State Vania Gava, the sides discussed the development of energy cooperation between Azerbaijan and Italy. The importance of the Trans-Adriatic Pipeline (TAP) was mentioned in strengthening Italy’s energy supply and its position in the European gas market.

Energy Minister Parviz Shahbazov said natural gas supply through TAP plays an important role in energy cooperation with Italy, Azerbaijan’s largest trading partner. The minister noted that by the end of the year, gas exports to Italy under short and long-term contracts were projected at 9.5 billion cubic meters, and by increasing the capacity of TAP, it is possible to supply more natural gas not only to Italy, but also to other European countries.

The sides also exchanged views on cooperation with Italian companies in the field of renewable energy, as well as support for the demining process of the liberated territories.

At the meeting with Energy Minister Bolat Akchulakov, the sides exchanged views on the bilateral cooperation between the two countries in the field of energy and the status of the energy markets. The opportunities associated with the transportation of Kazakhstan`s energy resources to the world market were evaluated. In addition to the transit of Kazakhstan`s oil and oil products through Azerbaijan, the measures taken at the level of working groups to deliver liquefied natural gas to Azerbaijan via the Caspian Sea were also discussed during the conversation.

Source: Azerbaijan State News Agency

Posted on

Azerbaijan`s Minister of Economy: Value added in refining industry increased by 12.2%

“As a result of promoting the activities of business entities and enterprises in our country, the growth rate of production in various fields has significantly accelerated,” Azerbaijan`s Minister of Economy Mikayil Jabbarov said on Twitter.

“In the refining industry, which is one of the priority areas in the development of the non-oil sector, value added increased by 12.2% in the first four months of this year, compared to the same period last year, and by 22.6% in the non-oil refining industry,” the minister tweeted.

Source: Azerbaijan State News Agency

Posted on

First CE-IVD marked AI solution for prognostic risk stratification of breast cancer patients.

Stratipath, a global leader in AI-based precision diagnostic solutions, today announced that its AI software for prognostic risk stratification of breast cancers, Stratipath Breast, is now CE-IVD marked.

Stockholm, Sweden, June 01, 2022 (GLOBE NEWSWIRE) — Stratipath, a global leader in AI-based precision diagnostic solutions, today announced that its AI software for prognostic risk stratification of breast cancers, Stratipath Breast, is now CE-IVD marked. This paves the way for clinical implementation in the European Union. Based on the analysis of digital histopathology whole slide images, stained with haematoxylin and eosin (H&E) the software provides novel decision support to clinicians and enables precision medicine for more patients.

Stratipath Breast is the first EU regulatory compliant solution for risk stratification of breast cancer using AI-based precision diagnostics to analyse cancer tissue, and enabling identification of patients with increased risk of disease progression.

In contrast to traditional molecular tests, AI-based risk stratification enables faster turnaround times for results, provides new information at the point of diagnosis and reduces the need for expensive molecular testing, allowing for wider use and benefit to more patients.

“Stratipath Breast offers a faster and cheaper alternative to molecular assays, allowing more patients to have access to precision diagnostics. By using Stratipath Breast, clinicians can diagnose with support from prognostic information, while reducing laboratory time and costs,” says Johan Hartman, professor in pathology at Karolinska Institutet, Stockholm, and co-founder of Stratipath.

Histological tumour grade is a strong prognostic indicator of breast cancer. Grading of invasive breast cancer is performed on all invasive breast cancers based on morphological assessment, according to the Nottingham Histologic Grade (NHG), resulting in the low- to high-risk categories NHG 1, 2 or 3. But currently, more than 50% of all breast cancer patients are categorised as of intermediate risk (i.e NHG 2), which provides little clinical utility for treatment decision-making. The consequential over- and undertreatment of patients with early breast cancer has become one of the main challenges for treating physicians, and the clinical decisions are often dependent on expensive molecular assays that are not accessible to the majority of patients.

Using deep learning, Stratipath Breast enables cancer detection and classification of intermediate risk tumours into low- and high-risk groups, based on grade-related tumour morphology. The stratification comes from a rigorous scientific development process and validation using multi-source real-world datasets, comprising histopathology images and associated clinical outcome data.

The system measures risk-associated morphological patterns locally in the image and aggregates this information across the analysed tissue area to establish whether the tumour belongs to the high- or low-risk group. Results from Stratipath Breast provide prognostic information and are intended to be used as a decision support tool, together with other clinical and pathological information.

Stratipath Breast provides an optimal workflow through integration with leading digital pathology solutions. It can also be used on its own, via the Stratipath customer web portal. Access to Stratipath Breast will be provided as a Software as a Service solution, by a subscription or pay as you use model. Not marketed in the USA.

About Stratipath
Stratipath is a spin-out from Karolinska Institutet in Stockholm, Sweden, bringing pioneering research in AI and precision medicine into clinical use. The company was founded in 2019 by Johan Hartman, M.D., PhD, Mattias Rantalainen, PhD and Fredrik Wetterhall with a mission to radically improve cancer treatment decisions and patient outcomes. Stratipath offers an AI precision diagnostic solution for healthcare and can offer an accelerated path for pharma and biotech companies to identify patients most likely to benefit from novel therapies.

Attachments

Lars Lengquist
Stratipath
+46 709574782
lars.lengquist.press@stratipath.com

 

Posted on

UK National Screening Committee Report Singles Out Eyenuk’s EyeArt as the Only Diabetic Eye Screening AI Technology Ready for Live Clinical Implementation in the National Health Service

LOS ANGELES, June 01, 2022 (GLOBE NEWSWIRE) — Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™ and AI Predictive Biomarkers™, announced today that its EyeArt® system has been confirmed to have “sufficient high quality evidence” as “safe and cost-effective,” and is the only diabetic eye screening AI technology ready for live clinical implementation in the United Kingdom, according to the report, “Automated grading in the Diabetic Eye Screening Programme- External review against programme appraisal criteria for the UK National Screening Committee.”

The comprehensive review of 10 AI algorithms’ performance, reported in peer-reviewed publications, was conducted for the UK National Screening Committee (NSC), which provides advice about all aspects of population screening to the National Health Service (NHS) and the ministers of the four UK countries (England, Scotland, Wales, and Northern Ireland).

The 169-page NSC report identified the EyeArt v2.1 algorithm for autonomous diabetic retinopathy screening as the only AI technology ready for live clinical implementation in the UK. Study authors concluded that “there is sufficient high-quality evidence from the EDESP (English Diabetic Eye Screening Program) that EyeArt v2.1 may be safe and cost-effective either using it for level 1 grading or as a filter prior to manual grading.”

The EyeArt system is now being planned for live clinical use within the North East London NHS Diabetes Eye Screening Programme as part of a project led by the Moorfields Eye Hospital NHS Foundation Trust and supported jointly by the NHSX AI Lab and the UK Health Foundation. The funded program will implement the live clinical use of artificial intelligence and assess its effectiveness in addressing racial and ethical health inequalities, and its acceptability by healthcare providers and people with diabetes.

“We are gratified by the NSC’s confirmation that the EyeArt system stands out from other solutions for its safety and cost-effectiveness and would like to thank our clinical collaborators within various diabetes eye screening programs (DESP) throughout the National Health Service,” said Kaushal Solanki, PhD, founder and CEO of Eyenuk. “We look forward to working with the Moorfields Eye Hospital and the North East London NHS DESP to deploy the EyeArt system for live clinical use.”

The UK has been leading the world in diabetic retinopathy screening, achieving patient uptake rates of over 80% (screening nearly 2.5 million diabetes patients annually). In most countries, fewer than half of diabetes patients receive annual eye screening. Thanks to the UK’s comprehensive screening program, it is the only country where diabetic retinopathy is no longer the leading cause of blindness in the working-age adults.

Eyenuk will showcase the EyeArt AI System during the American Diabetes Association’s 82nd Scientific Sessions in New Orleans, June 3-7. Attendees can visit booth #1709 to learn how the EyeArt system can help their organizations improve diabetes management and population health.

About Eyenuk, Inc.
Eyenuk, Inc. is a global artificial intelligence (AI) medical technology and services company and the leader in real-world AI Eye Screening™ for autonomous disease detection and AI Predictive Biomarkers™ for risk assessment and disease surveillance. Eyenuk is on a mission to screen every eye in the world to ensure timely diagnosis of life- and vision-threatening diseases, including diabetic retinopathy, glaucoma, age-related macular degeneration, stroke risk, cardiovascular risk, and Alzheimer’s disease. Find Eyenuk online on its website, Twitter, Facebook, and LinkedIn.

About the EyeArt AI System
The EyeArt AI System provides fully autonomous diabetic retinopathy (DR) screening, including retinal imaging, DR detection based on international clinical standards and immediate reporting, in a single office visit during a diabetic patient’s regular exam. Once the patient’s fundus images have been captured and submitted to the EyeArt AI System, the DR detection results are available in a PDF report in less than 30 seconds.

The EyeArt AI System was developed with funding from the U.S. National Institutes of Health (NIH) and is validated by the U.K. National Health Service (NHS). In addition to U.S. Food and Drug Administration (FDA) 510(k) clearance, the EyeArt AI System has CE marking as a class 2a medical device in the European Union and a Health Canada license. It is the most extensively validated AI technology for autonomous DR detection, tested on over 500,000 patients globally with 2 million images collected in clinical environments. It is designed to be General Data Protection Regulation (GDPR) and Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant. The EyeArt AI System is reimbursable by government and private payors in the U.S. under the newly created Category 1 Current Procedural Terminology (CPT) code 92229.

VIDEO: Learn more about the EyeArt AI System for Autonomous Detection of Diabetic Retinopathy

Media Contact
Todd Stein
+1 510 417 0612
todd@toddsteincommunications.com

Eyenuk, Inc. Contact
Frank Cheng, President & CCO
+1 818 835 3585
frank.cheng@eyenuk.com